1,090 Shares in Edwards Lifesciences Corp (NYSE:EW) Purchased by Bellecapital International Ltd.

Share on StockTwits

Bellecapital International Ltd. bought a new position in shares of Edwards Lifesciences Corp (NYSE:EW) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 1,090 shares of the medical research company’s stock, valued at approximately $201,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. FTB Advisors Inc. bought a new position in shares of Edwards Lifesciences in the first quarter worth $25,000. Evolution Wealth Advisors LLC bought a new position in shares of Edwards Lifesciences in the second quarter worth $29,000. Field & Main Bank bought a new position in shares of Edwards Lifesciences in the first quarter worth $34,000. WP Advisors LLC bought a new position in shares of Edwards Lifesciences in the first quarter worth $35,000. Finally, Parkside Financial Bank & Trust increased its position in shares of Edwards Lifesciences by 61.4% in the first quarter. Parkside Financial Bank & Trust now owns 247 shares of the medical research company’s stock worth $47,000 after purchasing an additional 94 shares during the period. 82.43% of the stock is owned by institutional investors.

NYSE:EW opened at $215.21 on Friday. The stock’s 50-day moving average is $201.20 and its 200-day moving average is $184.95. The company has a current ratio of 3.38, a quick ratio of 2.48 and a debt-to-equity ratio of 0.18. The stock has a market cap of $45.59 billion, a P/E ratio of 44.38, a price-to-earnings-growth ratio of 2.76 and a beta of 0.87. Edwards Lifesciences Corp has a 1-year low of $136.44 and a 1-year high of $219.71.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, July 23rd. The medical research company reported $1.38 EPS for the quarter, topping the Zacks’ consensus estimate of $1.33 by $0.05. The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.04 billion. Edwards Lifesciences had a return on equity of 31.25% and a net margin of 18.29%. The firm’s quarterly revenue was up 15.2% on a year-over-year basis. During the same period in the previous year, the firm earned $1.24 earnings per share. As a group, equities analysts forecast that Edwards Lifesciences Corp will post 5.34 EPS for the current year.

In other news, VP Donald E. Bobo, Jr. sold 5,369 shares of the company’s stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $216.26, for a total transaction of $1,161,099.94. Following the transaction, the vice president now directly owns 26,082 shares of the company’s stock, valued at $5,640,493.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Larry L. Wood sold 6,716 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $169.75, for a total value of $1,140,041.00. Following the transaction, the vice president now directly owns 124,102 shares in the company, valued at $21,066,314.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 137,579 shares of company stock worth $26,996,435. 1.63% of the stock is owned by insiders.

A number of research analysts recently commented on the company. Stifel Nicolaus raised their price target on Edwards Lifesciences from $190.00 to $200.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Raymond James raised their price target on Edwards Lifesciences from $200.00 to $232.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. BTIG Research restated a “hold” rating on shares of Edwards Lifesciences in a research report on Thursday, July 25th. Wells Fargo & Co raised their price target on Edwards Lifesciences from $207.00 to $220.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Finally, Citigroup set a $159.00 target price on Edwards Lifesciences and gave the company a “sell” rating in a research report on Friday, July 26th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and fourteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $204.74.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Story: Dividend Aristocrat Index

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.